Study of PX-866 and Docetaxel in Solid Tumors

NCT01204099 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

223

Enrollment

INDUSTRY

Sponsor class

Conditions

Non Small Cell Lung Cancer (NSCLC)
Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Interventions

DRUG: Docetaxel
DRUG: PX-866

Sponsor

Cascadian Therapeutics Inc.